Thermo Fisher Scientific Inc.
TMO
$585.51
-0.47%
Thermo Fisher Scientific, Inc. is a global leader in serving science, providing a broad portfolio of analytical instruments, laboratory equipment, diagnostics consumables, and life science reagents to pharmaceutical, biotech, academic, and clinical customers. The company operates through four segments—analytical technologies, specialty diagnostic products, life science solutions, and lab products and services (including CRO services)—which collectively position it as a one-stop shop for scientific research and clinical diagnostics. As the largest player in the life science tools industry, Thermo Fisher is currently in the spotlight for its robust revenue growth and raised long-term guidance, despite facing modest inflationary pressures and geopolitical uncertainties. The stock has recently surged to near its 52-week high, reflecting investor optimism about its operational resilience and strategic execution.…
TMO
Thermo Fisher Scientific Inc.
$585.51
Investment Opinion: Should I buy TMO Today?
We rate Thermo Fisher as a Buy, based on its strong competitive position, consistent growth, and reasonable valuation relative to its growth prospects. The analyst consensus is 'Buy' with an average target of $631.42, implying ~7.3% upside, and the high target of $750 suggests significant potential. The company's revenue growth of 6.2% YoY, operating margin of 18.2%, and free cash flow of $6.75B support the thesis.
Sign up to view all
TMO 12-Month Price Forecast
The AI model assesses Thermo Fisher as a solid long-term investment, given its consistent growth, strong margins, and defensive characteristics. The valuation is not excessive, and the company's leadership in life sciences tools provides a durable competitive advantage. However, the modest growth rate and potential inflation risks temper enthusiasm. The stance would be upgraded if growth accelerates above 8% or if the stock pulls back to a more attractive valuation (forward PE < 20x).
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $631.42 and implied upside of +7.8% versus the current price.
Average Target
$631.42
0 analysts
Implied Upside
+7.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$520 - $750
Analyst target range
The target price range spans from a low of $520.00 to a high of $750.00, representing a wide spread of 44% from low to high, which indicates significant uncertainty about the stock's future performance. The high target of $750 implies a 27.5% upside, likely assuming continued strong execution, margin expansion, and successful integration of acquisitions. The low target of $520 suggests a downside of 11.6%, possibly pricing in risks such as inflationary pressures, competitive threats, or a slowdown in research spending. The wide range reflects the diverse views among analysts, but the overall bullish consensus and recent price momentum suggest that the market is leaning toward the higher end of expectations.
Bulls vs Bears: TMO Investment Factors
Thermo Fisher presents a balanced risk/reward profile. The bull case is supported by consistent revenue growth, strong margins, and a diversified business model, while the bear case centers on valuation concerns and modest growth rates. Currently, the bull case has slightly stronger evidence given the company's operational resilience and analyst optimism, but the elevated valuation leaves little room for disappointment. The most critical tension is whether the company can accelerate growth to justify its premium multiple; if it does, the stock could reach the high target, but if growth stalls, a de-rating is likely.
Bullish
- Consistent Revenue Growth: Q1 2026 revenue grew 6.2% YoY to $11.01B, with sequential growth from Q2 2025 ($10.86B) through Q4 2025 ($12.22B), showing steady demand across segments. The company raised long-term guidance, reflecting confidence in continued expansion.
- Strong Profitability Metrics: Operating margin improved to 18.2% in Q1 2026 (from 17.8% in Q1 2025), and net margin held at 15.0%. Gross margin of 40.7% in Q1 2026 is robust, indicating pricing power and operational efficiency.
- Analyst Consensus Buy: With 26 analysts, the consensus rating is 'Buy' (mean score 1.54), and the average target price of $631.42 implies ~7.3% upside from the current $588.29. The high target of $750 suggests 27.5% upside, reflecting optimism about execution.
- Resilient Business Model: Diversified revenue streams (consumables and services each >$4.7B in Q1 2026) reduce dependence on any single product line. The company's beta of 0.85 indicates lower volatility than the market, appealing to risk-averse investors.
Bearish
- Elevated Valuation: Trailing PE of 32.6x and forward PE of 21.4x are premium to the market, with a PEG ratio of 4.54 suggesting overvaluation relative to growth. EV/EBITDA of 21.6x is also high, leaving little margin for error.
- Modest Growth Rate: Revenue growth of 6.2% YoY is moderate for a company with such a high multiple. If growth decelerates, the stock could face de-rating, as seen in the YTD decline of -0.7% despite a strong 3-month rally.
- Inflationary Pressures: Management flagged 'modest inflation' risk, which could compress margins if input costs rise faster than pricing. Q1 2026 gross margin of 40.7% is slightly below Q3 2025's 41.8%, indicating potential pressure.
- Geopolitical Uncertainties: Middle East tensions and other geopolitical risks could disrupt supply chains or dampen customer spending. The stock's recent volatility (e.g., a -31.45% max drawdown) highlights vulnerability to external shocks.
TMO Technical Analysis
Thermo Fisher's stock is in a strong uptrend, with a 1-year price change of +21.3%, significantly outperforming the S&P 500's +20.4% over the same period. The current price of $588.29 sits at 91.4% of the 52-week range (between $435.27 low and $643.99 high), indicating the stock is trading near its highs, which suggests robust momentum but also potential overextension. The 6-month price change of +16.5% further confirms the sustained upward trajectory, though the YTD change of -0.7% shows the stock has only recently recovered from earlier weakness.
Beta
0.85
0.85x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$435-$644
Price range past year
Annual Return
+19.7%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | +10.0% | +4.0% |
| 3m | +30.7% | +5.3% |
| 6m | +14.0% | +12.6% |
| 1y | +19.7% | +20.1% |
| ytd | -1.2% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Thermo Fisher's revenue trajectory is solidly growing, with Q1 2026 revenue of $11.01 billion, up 6.2% year-over-year from $10.36 billion in Q1 2025. This marks a continuation of sequential growth, as Q4 2025 revenue was $12.22 billion, Q3 2025 was $11.12 billion, and Q2 2025 was $10.86 billion, indicating a steady upward trend. The growth is broad-based, with consumables and services each contributing over $4.7 billion in the latest quarter, while instruments added $1.56 billion, reflecting the company's diversified revenue streams. The 6.2% YoY growth, while modest, is consistent with the company's mature market position and its ability to generate stable demand across its segments.
Quarterly Revenue
$11.0B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
40.7%
Latest Quarter
Free Cash Flow
$6.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Given that Thermo Fisher has positive net income, the PE ratio is the most appropriate valuation metric. The trailing PE is 32.6x, while the forward PE is 21.4x, implying the market expects significant earnings growth. The gap between trailing and forward PE suggests that analysts anticipate a substantial increase in EPS, which is supported by the estimated EPS of $39.07 for the next fiscal year. This forward multiple is at a premium to the broader market, but it is justified by the company's consistent growth and strong competitive position in the life sciences tools industry.
PE
32.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 24x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.74, which is manageable but not negligible, and interest expenses of $354M in Q1 2026. The company's free cash flow of $6.75B TTM provides ample coverage, but a rising debt load could strain if rates stay high. The payout ratio is low at 9.4%, so dividends are safe, but the low yield (0.29%) offers little income support. Revenue concentration is diversified across segments, but any slowdown in pharma/biotech R&D spending could hit growth, as seen in the modest 6.2% YoY growth in Q1 2026.
FAQ
The key risks include: 1) Valuation risk - if growth slows, the premium multiple could compress, leading to a de-rating. 2) Inflation risk - rising costs could pressure margins, as flagged by management. 3) Competitive risk - rivals like Danaher and Agilent could take market share. 4) Macro risk - a recession could reduce R&D spending, impacting revenue. The most severe risk is a combination of these factors, which could drive the stock down to the 52-week low of $435.27, a -26% decline.
The 12-month forecast is moderately bullish. The base case (50% probability) sees the stock reaching $600-650, with an average target of $631. The bull case (30% probability) targets $650-750, driven by accelerated growth. The bear case (20% probability) sees the stock falling to $435-520 if growth disappoints. Overall, the most likely scenario is the base case, with steady growth and modest upside. Investors should monitor quarterly earnings for signs of acceleration or deceleration.
TMO is fairly valued relative to its growth prospects. The forward PE of 21.4x is in line with the market, but the PEG ratio of 4.54 suggests it is expensive relative to its growth rate. However, the company's consistent 6% revenue growth and 18% operating margins justify a premium. Compared to its own history, the forward PE is below the 5-year average of ~25x, indicating the stock is not overvalued. The market expects continued earnings growth, which is reflected in the analyst estimates.
TMO is a good buy for investors seeking a stable, growing company in the life sciences sector. With an average analyst target of $631.42, the stock offers ~7.3% upside, and the high target of $750 suggests 27.5% potential. The main risk is valuation, as the forward PE of 21.4x is not cheap, but the company's consistent growth and strong margins justify a premium. For long-term investors, TMO is a solid addition, but for short-term traders, the stock's recent run-up may limit upside.
TMO is best suited for long-term investment, given its stable growth, low beta (0.85), and defensive characteristics. The company's consistent revenue growth and strong cash flow make it a reliable compounder. Short-term trading is possible, but the stock's low volatility and modest upside in the near term may not offer significant opportunities. A minimum holding period of 3-5 years is recommended to fully realize the benefits of its growth and dividend growth.